|
Synonyms: HuMab 002 [2] | LC1004-002 | RO-4905417 | RO4905417
Compound class:
Antibody
Comment: Inclacumab (formerly RO4905417) is an IgG4κ monoclonal antobody that targets selectin P (CD62; SELP) [2] that was initially designed for potential to promote anti-inflammatory and antithrombotic effects as a mechanism to reduce atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Inclacumab was later repositioned to reduce vaso-occlusive crises in patients with sickle cell disease.
|
| No information available. |
Summary of Clinical Use  |
| Development in atherosclerosis has been terminated. Global Blood Therapeutics redirected development to determine the efficacy of inclacumab to reduce vaso-occlusive crises (VOCs) in sickle cell disease patients. The FDA granted orphan drug designation [1] and pediatric disease designation in mid-2022 which permits the use of inclacumab to treat patients with sickle cell disease. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04935879 | A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises | Phase 3 Interventional | Global Blood Therapeutics | ||
| NCT04927247 | A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | Phase 3 Interventional | Global Blood Therapeutics | ||
| NCT05348915 | A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease | Phase 3 Interventional | Global Blood Therapeutics | ||
